News

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the investigational therapy onvansertib as a potential treatment for chronic myelomonocytic leukemia…

An approved treatment regimen using the oral therapy Zenbexus (iberdomide) can reduce the risk of disease progression among people with hard-to-treat multiple myeloma,…

An experimental therapy containing a specific ratio of two naturally occurring pancreatic enzymes may be able to reduce the growth of certain cancers, including…

An arm of the European Medicines Agency (EMA) — which reviews clinical trial data for drugs under regulatory review in the European Union — has…

A first-in-human clinical trial testing Orum Therapeutics‘ infusion therapy ORM-1153 in people with hard-to-treat acute myeloid leukemia (AML), a form of blood cancer, has…

A new study by U.S. researchers suggests that using high-potency chemotherapy in myeloma as part of bridging therapy — medications given before patients are…

The experimental cancer vaccine SurVaxM may improve survival in people with newly diagnosed glioblastoma, an aggressive form of glioma. The therapy’s developer, Mimivax,…

Infections affecting nearly three-quarters of people with myeloma taking part in clinical testing for the now-approved treatment Lynozyfic (linvoseltamab-gcpt) sparked evolving “infection protection”…

The U.S. Food and Drug Administration’s (FDA) recent approval of Takeda‘s injection therapy Mimrylo (rusfertide) to treat excessive blood cell production in adults with…

Adding the experimental anti-CD38 therapy felzartamab reduced the risk of disease progression among people with hard-to-treat myeloma in a Phase 3 clinical trial conducted…